PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026Cellular and Molecular Immunology0 citationsOpen Access

Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection

CDCostanza DieliMSMarta Di SimoneFDFrancesco Dieli

Key Points

  • This research aims to explore the effects of oncolytic viruses on immune suppression in glioblastoma multiforme.
  • Intravenous administration of oncolytic alphavirus M1
  • Assessment of GBM growth suppression
  • Evaluation of systemic immunosuppression levels
  • Oncolytic alphavirus M1 suppressed glioblastoma growth
  • M1 administration reversed systemic immunosuppression associated with GBM

Abstract

Glioblastoma multiforme (GBM) is a lethal primary brain cancer for which treatment has limited options, characterized by systemic and local immunosuppression that contributes to the malignancy's aggressiveness and resistance to therapy.In a recent study published in Cellular and Molecular Immunology 1, Han et al. reported that intravenously administered oncolytic alphavirus M1 not only suppressed GBM growth but also reversed GBM-induced systemic immunosuppression.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dieli et al. (2026) studied this question.

synapsesocial.com/papers/69bf8692f665edcd009e8eb3https://doi.org/10.1038/s41423-026-01401-2
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen2026
  2. 2IMMU-83. CD4 T-cell reprogramming via oncolytic virotherapy enhances survival in glioblastoma2025
  3. 3Breaking Immune Isolation in Glioblastoma2026 · 1 citations
  4. 4Microglia in Glioblastomas: Molecular Insight and Immunotherapeutic Potential2024 · 5 citations
  5. 5EP08.01 THE IMMUNE LANDSCAPE OF BRAIN TUMORS: IMPLICATIONS FOR NEUROIMMUNOLOGY AND NEURO-ONCOLOGY THERAPIES2025